

# Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics

Giovanni Montesano, MD, PhD,<sup>1,2</sup> Alessandro Rabiolo, MD,<sup>3,4</sup> David F. Garway-Heath, MD,<sup>1</sup> Dun Jack Fu, MD, PhD,<sup>1</sup> Gus Gazzard, MD,<sup>1</sup> Giovanni Ometto, PhD,<sup>1,2</sup> David P. Crabb, PhD,<sup>2</sup> Anthony P. Khawaja, PhD, FRCOphth<sup>1</sup>

**Purpose:** To test the association between use of calcium channel blocker (CCB) medications and the rate of visual field (VF) progression in a large cohort of patients from 5 glaucoma clinics.

**Design:** Retrospective longitudinal case-control study.

**Subjects:** Patients attending 5 glaucoma clinics in the United Kingdom using the same electronic medical record (EMR) system.

**Methods:** For the main analysis, we selected 1 eye from patients with at least 5 reliable (false positive errors < 15%) VFs over a period of at least 4 years. The use of systemic medications was derived from the EMR system. Calcium channel blocker users were identified as cases. Propensity score matching (PSM) and multivariable analyses (MVAs) were used to adjust for confounders. A directed acyclic graph of the relevant variables guided the selection of covariates. Linear mixed-effect models (LMMs) were used to test the effect on the rate of VF mean deviation (MD) associated with CCB use and other covariates (for the MV analysis). Sensitivity analyses were conducted with different inclusion criteria and cutoffs on the estimated duration of CCB use.

**Main Outcome Measures:** The mean difference in the rate of VF MD progression between CCB users and controls.

**Results:** The main analysis included 14 475 eyes (1942 from CCB users) that met the selection criteria (1 eye per patient). The median (interquartile range) VF series length was 8 (6, 11) tests, with a follow-up of 8.6 (6, 11.5) and 8.2 (5.9, 11.2) years in CCB users and controls, respectively. One-to-one PSM pairing with controls was achieved for all CCB users. The estimated rate of MD progression was  $-0.31$  ( $-0.33$  to  $-0.28$ ) dB/year (mean [95% confidence intervals]) in the CCB users and  $-0.35$  ( $-0.37$  to  $-0.33$ ) dB/year in the matched controls ( $P = 0.016$ ). This significant difference was confirmed with the MV analysis including all controls ( $P = 0.020$ ). All sensitivity analyses confirmed the main results.

**Conclusions:** Calcium channel blocker use was statistically significantly associated with a slower rate of VF deterioration after multivariable adjustment. The estimated difference was small and likely not clinically significant but may be influenced by the limited information on the duration of CCB exposure in this cohort.

**Financial Disclosure(s):** Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. *Ophthalmology Glaucoma* 2025;8:333-342 © 2025 by the American Academy of Ophthalmology. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).



Supplemental material available at [www.ophtalmologyglaucoma.org](http://www.ophtalmologyglaucoma.org).

Calcium channel blockers (CCBs) are some of the most commonly prescribed medications for cardiovascular conditions. Up to 40% of patients with systemic hypertension are prescribed a CCB<sup>1</sup> to control their blood pressure. In the United Kingdom, CCBs make up approximately 4% of all primary care prescriptions.<sup>2</sup> Because the incidence of both systemic hypertension<sup>3</sup> and glaucoma<sup>4</sup> increases with age and because of the known association between these 2 conditions,<sup>5,6</sup> many patients who are at risk of, or have, glaucoma are likely to be prescribed CCBs.

The effect of systemic CCBs on glaucoma is controversial. Many large observational investigations have consistently shown an association between CCB use and increased risk of receiving a glaucoma diagnosis,<sup>7-11</sup> replicating this result across different cohorts. Other studies have also shown an association between CCB use and glaucoma-related traits, such as thinner inner retinal layers on OCT imaging.<sup>10,12</sup> On the other hand, studies investigating the association between CCBs and disease progression in patients with glaucoma have shown either no association<sup>13</sup>

or a protective association,<sup>14–17</sup> especially in normal tension glaucoma (NTG). Two of the studies showing a protective effect were small randomized clinical trials (RCTs).<sup>14,15</sup>

However, well-powered studies of the association between CCB use and the rate of glaucoma progression are still lacking. In this work, we analyzed real-world data from more than 14 000 patients followed in 5 glaucoma clinics across the United Kingdom. We investigated the association between systemic CCB use and the rate of visual field (VF) progression, adjusting for multiple confounders. We further report on the association of the rate of VF progression with the use of systemic medication classes and multiple patient characteristics.

## Methods

### Clinical Cohort

Patient data from 5 National Health Service glaucoma clinics in England were extracted from an ophthalmic electronic medical record (EMR) (Medisoft, Medisoft Ltd). This database was created in 2015 as part of the Royal College of Ophthalmologists National Ophthalmology Database audit.<sup>18</sup> All patient data were anonymized upon data extraction and stored in a secure database at City St George's, University of London. Subsequent analyses of this dataset were approved by a research ethics committee of City, University of London, in accordance with the Declaration of Helsinki and the General Data Protection Regulation of the European Union. The requirement for informed consent was waived because of the retrospective nature of the study. The dataset contained Humphrey Field Analyzer (Zeiss Meditec) VF data for 145 562 eyes of 73 990 patients. We selected tests performed with a 24-2 pattern and any Swedish Interactive Threshold Algorithm (SITA) strategy<sup>19</sup> with < 15% false-positive error rate.<sup>20</sup> A mixture of VF SITA Standard and Fast was allowed because the use of SITA Fast, despite its slightly lower precision, is unlikely to make a sizeable difference for measuring VF progression.<sup>21</sup> The series were truncated at the time of glaucoma surgery (any incisional surgery or cyclodestructive procedure). Eyes which received glaucoma surgery before their earliest VF tests were excluded. We excluded eyes with documented comorbidities other than glaucoma. One eye per patient was selected when both were includible, preferring an eye with a manually entered diagnostic label of glaucoma for 1 eye, or at random when both eyes had the same label or no label.

For our main analysis, we selected a series with at least 5 tests performed over at least 4 years. Following previous methodology for analyses on the same dataset,<sup>22–24</sup> the series needed to contain at least 2, not necessarily consecutive, VFs with a mean deviation (MD) less than  $-2$  dB (95% lower limits of normality for Humphrey field analyzer<sup>22</sup>). This increased the likelihood of including eyes with perimetric defects from glaucoma during the course of their follow-up, without relying on the diagnostic labels reported by clinicians. A sensitivity analysis was conducted without applying this criterion (see later).

Other information recorded in the EMR included baseline age, sex, self-reported ethnicity, index of multiple deprivation (IMD),<sup>25,26</sup> diabetic status, best-corrected visual acuity (BCVA), intraocular pressure (IOP), ocular medications, ocular diagnoses, and ocular surgeries (with dates). Higher IMD scores indicate more deprivation. The IMD score was standardized for the multivariable analyses (MVAs) by subtracting the sample mean (15.6) and dividing by the sample standard deviation (SD) (11.9) calculated

from the main analysis cohort, for consistency. More than 90% of the cohort reported “White” as their ethnicity. Because of the low representation of non-White patients in these cohorts, they were not further subdivided into more specific ethnic groups.

This selection led to the inclusion of 14 475 eyes (1 per patient) and 133 505 VF tests. A detailed flowchart of the selection steps is reported in a [Supplementary Appendix](#) (available at [www.ophtalmologyglaucoma.org](http://www.ophtalmologyglaucoma.org)). Different selection strategies were assessed in our sensitivity analyses, which are summarized later.

### Systemic Medications

Medical staff could manually enter systemic medications into the EMR, as per standard clinical practice, which are recorded as active components or brand names. These were automatically classified by the EMR into broader categories. All classifications were manually reviewed. Brand names were converted into their active component names. All fixed combinations were split into their individual components. The categories that were identified for systemic medications are reported in [Table 1](#). The category identified as “*Other anti-hypertensives*” included angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEis), direct renin inhibitors,  $\alpha$ 2A-adrenergic agonists,  $\alpha$ 1-adrenergic blockers, direct vasodilators, and medications for pulmonary hypertension.

The records include a start and end date for each medication. However, the recorded start dates do not necessarily represent the effective day the medication was initiated, but rather the first date it was recorded into the system. A separate field explicitly reporting the start of the medication was available but was often left empty. Exposure to medications for the main analysis was, therefore, based on any report of the use of the medication in the EMR at any point in time. Sensitivity analyses for CCBs were conducted requiring an estimated exposure for at least 20% of the VF follow-up time or modelling exposure as a continuous value (see later).

### Statistical Analysis

This was a retrospective longitudinal case-control study. All analyses were performed in R (R Foundation for Statistical Computing). The primary outcome measure was the difference in the rate of VF progression, measured with a linear mixed model (LMM), and associated with an exposure to CCBs. All other results are to be considered exploratory. The Strengthening the Reporting of Observational Studies in Epidemiology checklist<sup>27</sup> for case-control studies is provided as [STROBE-checklist](#) (available at [www.ophtalmologyglaucoma.org](http://www.ophtalmologyglaucoma.org)).

The outcome variable of the LMM was the MD, regressed over time as a continuous variable (in years). The coefficient associated with time measured the rate of MD progression (in dB/year). An interaction term between time and use of medications, such as CCBs, modeled the difference in rate associated with exposure (the outcome measure for this study). Random intercepts and slopes modeled the variation in baseline damage and rate of MD progression across individuals. The LMMs were calculated using the *lme4*<sup>28</sup> and *lmerTest*<sup>29</sup> packages for R. The significance threshold was set at  $P = 0.05$ .

Because of the retrospective observational nature of this study, covariate adjustment was required to increase precision and reduce the risk of bias in the estimated association between CCBs and the rate of VF progression. The choice of covariates for adjustment was based on a directed acyclic graph (DAG) (provided as [Supplementary Appendix](#)). The DAG lays out the assumptions about possible direct and indirect correlations and causal links between the variables in the dataset. Various algorithms exist to find optimal solutions for a DAG, which return valid sets of

Table 1. Demographics for the Main Selection Cohorts—At Least 5 Visual Field Tests Over at Least 4 Years, with at Least 2 Nonconsecutive Mean Deviation Values less than −2 dB

	CCB Users N = 1942*	Matched Controls N = 1942*	P Value†	All Controls N = 12 533*	P Value†
Demographics					
Age (yrs)‡	71 (65–77)	72 (65–78)	0.038	68 (59–75)	< 0.001
Sex‡			0.460		0.901
Female	1016 (52%)	1039 (54%)		6538 (52%)	
Male	926 (48%)	903 (46%)		5995 (48%)	
Ethnicity‡			0.726		0.375
Non-White	39 (2.0%)	36 (1.9%)		216 (1.7%)	
White	1903 (98%)	1906 (98%)		12 317 (98%)	
IMD score‡	12 (7, 22)	12 (7, 22)	0.462	12 (7, 20)	0.124
Diabetes‡			0.443		< 0.001
No diabetes	1494 (77%)	1518 (78%)		11 001 (88%)	
Type 1	26 (1.3%)	19 (1.0%)		88 (0.7%)	
Type 2	422 (22%)	405 (21%)		1444 (12%)	
Cataract surgery‡			0.564		< 0.001
Phakic	1231 (63%)	1201 (62%)		10 096 (81%)	
Pseudophakic	62 (3.2%)	69 (3.6%)		203 (1.6%)	
CS during follow-up	649 (33%)	672 (35%)		2234 (18%)	
Baseline MD (dB)‡	−3.1 (−6.0 to −1.6)	−3.1 (−5.9 to −1.6)	0.708	−3.1 (−6.0 to −1.6)	0.785
Baseline PSD (dB)‡	2.71 (1.84–5.73)	2.69 (1.83–5.47)	0.472	2.6 (1.8–5.8)	0.208
VF tests (N)	8.0 (6.0–11.0)	8.0 (6.0–11.0)	< 0.001	8.0 (6.0–11.0)	0.024
Follow-up (yrs)	8.57 (6.05–11.52)	8.08 (5.87–11.05)	0.001	8.20 (5.88–11.24)	< 0.001
Baseline VA (LogMAR)	0.20 (0.00–0.20)	0.20 (0.00–0.30)	0.091	0.10 (0.00–0.20)	< 0.001
Average IOP (mmHg)	16.8 (14.7–19.0)	16.7 (14.3–19.1)	0.104	17.0 (14.7–19.5)	0.190
Highest IOP (mmHg)	21 (18–26)	21 (17–25)	0.072	21 (18–26)	0.616
Diagnostic label‡			0.457		0.940
POAG	822 (42%)	784 (40%)		5274 (42%)	
PACD	58 (3.0%)	58 (3.0%)		391 (3.1%)	
Other	1062 (55%)	1100 (57%)		6868 (55%)	
Medications					
Diuretics‡	768 (40%)	749 (39%)	0.532	1585 (13%)	< 0.001
Other antihypertensives‡	1191 (61%)	1185 (61%)	0.843	2231 (18%)	< 0.001
Nitrates‡	180 (9.3%)	158 (8.1%)	0.210	289 (2.3%)	< 0.001
Statins‡	996 (51%)	993 (51%)	0.923	2137 (17%)	< 0.001
Corticosteroids‡	226 (12%)	225 (12%)	0.960	651 (5.2%)	< 0.001
Beta-blockers‡	475 (24%)	469 (24%)	0.822	1184 (9.4%)	< 0.001
Psychoactive drugs‡	309 (16%)	369 (19%)	0.011	1104 (8.8%)	< 0.001
Metformin‡	236 (12%)	228 (12%)	0.692	519 (4.1%)	< 0.001

CCB = calcium channel blocker; CS = cataract surgery; IMD = index of multiple deprivation; IOP = intraocular pressure (during follow-up); LogMAR = logarithm of the minimum angle of resolution; MD = mean deviation; Other = unclassified, not updated or classified as ocular hypertension/glaucoma suspect but meeting the selection criteria; PACD = primary angle-closure disease; POAG = primary open-angle glaucoma; PSD = pattern standard deviation; VA = visual acuity; VF = visual field.

\*Median (interquartile range); n (%).

†Wilcoxon rank sum test; Pearson chi-square test.

‡Included in propensity score matching.

adjustment variables to minimize the effect of confounders and avoid sources of collider bias when estimating the association between specific exposures and outcomes. Note that, even with the same DAG, different adjustment sets may be required to estimate associations between different exposures and outcomes. For this study, we used the maximal (most extensive) valid set of covariates calculated with the package *dagitty*<sup>30</sup> for R based on the assumed DAG (the *canonical* set in the terminology of the software package). The DAG and the adjustment set was defined and locked before the analysis. The model was therefore fully prespecified before the analysis. Of note, the IOP and number of medications were not selected as covariates because, in a clinical context, they are influenced by VF progression (faster progressing patients are more heavily treated to lower IOPs than stable patients). Inclusion of these covariates could therefore introduce a collider bias. There was, however, no

difference in IOP between CCB users and controls (see Table 1). It is also interesting to note that, based on the assumed DAG, the same adjustment set could be used to estimate the association between the systemic medications included in the analysis and VF progression.

Covariate adjustment was carried out with 2 different methods. For the main analysis, we performed a propensity score matching (PSM) to generate a control group (CCB nonusers) matched 1:1 to the exposed group (CCB users) according to the adjustment set of covariates. We used the package *MatchIt*<sup>31</sup> for R (logistic model). For PSM, we also imposed a strict 1:1 matching for the diagnostic labels, so that we could perform a fully matched analysis with and without patients with diagnostic labels compatible with primary angle-closure disease. The proportion of eyes labeled as primary open-angle glaucoma (POAG) or other (which included those with no label) were also balanced. The LMM for the comparison

between the exposed group and matched controls included only 1 interaction term between time and CCB use (binary), modeling the observed difference in the rate of progression associated with exposure to CCBs. For the secondary analysis, a multivariable LMM was used. This analysis included all eyes that met the criteria for analysis. The LMM included the covariates via multiple interaction terms between time and each covariate of interest. Similar to the CCBs in the main analysis, each interaction term coefficient measured the change in the rate of progression associated with each covariate.

Missing data were imputed using the method of multivariable imputation by chained equations, as implemented in the *mice*<sup>32</sup> package for R, using all available demographics. Single imputation was chosen because of the low percentage of missing data (< 10%, see Results), to reduce computational complexity and to generate a unique dataset that could be adapted for both PSM and the MVAs.

An indicative minimum sample size was determined for the main analysis using the methodology described in Montesano et al,<sup>33</sup> assuming 1 test every year for 8 years, a SD for the MD of 1.97 dB and an average rate of progression of -0.38 dB/year. A sample of 1500 eyes per group provided 92% power to detect a 15% difference in the rate of progression at a significance level of  $P < 0.05$ .

### Sensitivity and Supplementary Analyses

Additional analyses were carried out to assess the sensitivity of our results to changes in the selection criteria and assumptions regarding the exposure to CCBs. The following are reported as supplementary material:

1. inclusion of all eyes with at least 2 reliable VFs over 1 year of follow-up prior to any glaucoma surgery;
2. multivariable analysis in the main selection cohort using a continuous-valued CCB exposure fraction (estimated proportion of follow-up time exposed to CCBs);
3. multivariable analysis excluding patients on nondihydropyridines in the main analysis cohort;
4. exposure to CCBs defined as exposure for at least 20% of the follow-up time; and
5. multivariable analysis isolating the effect of ARBs and ACEi in the main analysis cohort, since they both have been associated with a reduced chance of progression in some subgroups of patients.<sup>13</sup>

## Results

### Cohort Characteristics

We identified 1942 out of 14 475 (13%) patients exposed to systemic CCBs. Of these, 87% were using dihydropyridines (54% amlodipine), and 13% were using nondihydropyridines (10%

diltiazem, 3% verapamil). The average exposure among CCB users was 32% (median [interquartile range] 23% [0%, 52%]). The characteristics of the exposed cohort, of all controls and of the 1942 matched controls identified via PSM, are reported in Table 1. All variables considered for PSM were well balanced between CCB users and matched controls. A statistically significant difference ( $P < 0.05$ ) was still present for baseline age, but both the median and the interquartile range were very similar, differing at most by 1 year. Some variables, such as the highest IOP, the average IOP, and the baseline BCVA were also well balanced, despite not having been considered for PSM. Other variables, such as the length of the follow-up and the number of tests, showed a strongly statistically significant difference ( $P < 0.01$ ) but were very similar in their median and IQR. The missing data were imputed for age (1 of 14 475; < 0.01%), IMD score (691 of 14 475; 4.8%), diabetes type (287 of 1980; 14.5% of patients with diabetes, 2% of the total), ethnicity (1157 of 14 475; 8%), and baseline VA (1031 of 14 475; 7.1%).

### Associations with Rate of Progression

The results of the analysis on CCB-exposed and PSM-matched controls are reported in Table 2. Exposure to CCBs was associated with a significantly slower rate of progression ( $P = 0.016$ ). No difference was found in the estimated baseline MD, as expected from the PSM (see Table 1). The analysis was also repeated by excluding 116 eyes that had a diagnostic label suggestive of an angle-closure mechanism, with no material difference in the results.


These results were also confirmed by the MVA (Fig 1). The estimated rate for the “reference” patient was -0.34 [-0.41 to -0.28] dB/year (mean [95% confidence interval]), very similar to the estimated rate for the matched control group obtained with PSM (Table 2). The estimated difference in rate associated with the use of CCBs was 0.03 (0.01, 0.06) dB/year ( $P = 0.020$ ), similar to the difference in Table 2. Similar results were obtained by including or excluding patients with a diagnostic label suggestive of angle closure ( $P = 0.025$ ). Other significant detrimental associations were found with older baseline age, higher baseline PSD, more positive baseline MD, presence of diabetes, and the use of systemic corticosteroids. Female sex was associated with a slower rate of MD progression ( $P = 0.048$ ) in the full cohort. A table with the results from the multivariable LMM is reported in the Supplementary Appendix.

The secondary and sensitivity analyses confirmed these results and are reported in detail in the Supplementary Appendix. Similar results were obtained by redefining the use of CCBs as an estimated exposure of at least 20% (CCB users = 1044,

Table 2. Results from the Linear Mixed Model Comparing Calcium Channel Blocker (Any Exposure) Users and Matched Controls

	Matched Controls		CCB Users		Differences		P Value
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI	
All							
Baseline (dB)	-4.2	-4.5 to -4.0	-4.4	-4.6 to -4.1	-0.10	-0.41 to 0.20	0.5
Rate of progression (dB/yr)	-0.35	-0.37 to -0.33	-0.31	-0.33 to -0.28	0.04	0.01 to 0.08	0.016
PACD excluded							
Baseline (dB)	-4.3	-4.5 to -4.1	-4.4	-4.6 to -4.1	-0.09	-0.40 to 0.22	0.6
Rate of progression (dB/yr)	-0.35	-0.37 to -0.32	-0.31	-0.33 to -0.28	0.04	0.01 to 0.08	0.016

CCB = calcium channel blocker; CI = confidence interval; PACD = primary angle-closure disease.



**Figure 1.** Results of the multivariable linear mixed model analysis. The graph reports the estimated effects for the interaction between each variable and time. This represents the additive effect of each variable on the rate of progression of the mean deviation over time. The 95% confidence intervals are represented with horizontal bars. Significant  $P$  values ( $< 0.05$ ) are reported. For better visibility, the estimates are reported for 5 dB change for MD and PSD and by decade for baseline age. For this analysis, the “reference” patient was 67 years old, White, male, not diabetic, average IMD score, 0 dB MD and PSD at baseline, phakic at baseline, no cataract surgery during follow-up, and not on any of the included systemic medications. Age, baseline MD, and baseline PSD were rescaled for better visibility. CCB = calcium channel blocker; CI = confidence interval; CS = cataract surgery; DM = diabetes mellitus; IMD = index of multiple deprivation; MD = mean deviation; PACD = primary angle-closure disease; PSD = pattern standard deviation.

$P = 0.005$  for PSM analysis) and by removing patients on nondihydropyridines (258 of 1942 CCB users,  $P = 0.034$ ). The “dose-response” analysis showed a significant positive association with the exposure fraction (0.13 [0.07, 0.19] dB/year per fraction point,  $P < 0.001$ , [Supplementary Appendix](#)), which was maintained after restricting the analysis to the 1044 CCB users (0.16 [0.08, 0.24] dB/year per fraction point,  $P < 0.001$ ). Calcium channel blockers were also significantly associated with slower rates of MD progression ( $P = 0.004$  for PSM analysis), when all patients with at least 2 reliable VFs over 1 year prior to glaucoma surgery were included ( $N = 36\ 146$ , CCB users = 5104). Other associations in the multivariable LMM became significant with this extended cohort (see [Supplementary Appendix](#)). Angiotensin receptor blockers, but not ACEis, were also found to have a significant association with slower rates of progression ( $P = 0.015$ , MVA) when analyzed separately from other antihypertensives in the main selection cohort ([Supplementary Appendix](#)).

## Discussion

In this work, we analyzed the association between exposure to systemic CCB use and rate of VF loss in a large, real-world cohort of patients from glaucoma clinics in the United Kingdom. We found a significant association between CCB use and a marginally slower rate of progression, after adjusting for multiple confounders. We confirmed this

finding with additional sensitivity analyses, using either a less stringent criteria for the inclusion of patients in the analyzed cohort or a more stringent criteria for the definition of CCB exposure. All analyses, however, confirmed an estimated small average difference in the rate of VF deterioration between CCB users and controls, which is likely not clinically significant. However, this should be interpreted in the context of the limited information regarding CCB exposure in this cohort, which might dilute the magnitude of the true association.

This is the first large-scale real-world analysis of the association between systemic CCB and VF progression. Our findings are in general agreement with previous literature looking at the association between CCB use and the rate of VF progression. Koseki et al<sup>14,15</sup> published the results of 2 small placebo-controlled RCTs investigating the effect of brovincamine and nilvadipine on the rate of VF progression in patients with NTG. Both studies found a significant neuroprotective effect of the CCB under study. They also investigated the difference in the rate of MD progression with the LMMs. The effect was much larger (0.7 dB/year or 90% reduction with brovincamine and 0.26 dB/year or 96% reduction with nilvadipine) compared to our results (0.04 dB/year or 11% reduction in those exposed to CCBs). These differences can be explained by several factors, primarily the retrospective observational nature of our study. In fact, for most of the patients in our cohort, we had very little information regarding the period of exposure and the dosage

of CCBs. There were also significant differences in the study cohorts, because Koseki et al recruited patients with NTG who were randomized to CCB treatment, rather than a varied real-world cohort of patients from glaucoma clinics who were prescribed CCBs as treatment for other systemic conditions.

Daugeliene et al<sup>16</sup> published a small retrospective analysis on 47 patients with NTG (24 taking CCBs) and reported a significant protective association between CCB use and rate of MD progression (0.25 dB/year or 47% slower). Pappelis et al<sup>13</sup> analyzed a larger cohort of 250 patients with POAG and 112 glaucoma suspects. In contrast to Daugeliene et al and our results, they found no significant association between any of the systemic medications (including CCBs) and the rate of MD progression. There are, however, important differences between our analysis and Pappelis et al. For example, they used a quantile regression on the median rate, which would be relatively insensitive to changes in the negative tail of the distribution of rates of progression and would not account for the length of the test series. Moreover, they selected their variables based on the Akaike information criterion.<sup>34</sup> Optimizing prediction, however, does not generally lead to estimating an unbiased association between specific exposures and outcomes.<sup>35</sup> For example, adjusting for the number of medications and treated IOP, which are known to be reactive to VF progression in clinical practice (i.e., fast progressing patients will be treated more aggressively to lower IOP), carries the risk of introducing a collider bias.<sup>30,35</sup>

In our model, we overcome many of the previous limitations. We calculated the effect of CCB exposure (and other variables) on the mean rate of progression with LMMs. This is justified by previous evidence that most of the differences in the rates of VF progression across different populations or treatments are reflected by the negative tail of the distributions.<sup>36,37</sup> Moreover, the LMMs would account for different series length, by “shrinking” the effect of shorter VF series.<sup>38</sup> Finally, our multivariable adjustments were based on a DAG accounting for known and potential associations between variables. The adjustment set was specified prior to the analysis to estimate the association between exposure and outcome. Based on the DAG, this did not include adjustments for IOP control to avoid collider bias. However, no significant difference was found between CCB users and controls for any of the IOP-related metrics (see [Table 1](#)).

One interesting finding from Pappelis et al<sup>13</sup> was the protective association between the use of ACEis and ARBs and reduced risk of conversion to POAG in glaucoma suspects as well as an association of ARBs with a slower rate of progression (although not significant, except in a more advanced age). Our analysis was designed to investigate the association between the rate of VF progression and exposure to CCBs, but the same set of covariate adjustments could be used to explore the effect of other systemic medications according to the assumed DAG. In one [Supplementary analysis](#), we found a significant association between ARBs and a slower rate of MD progression, in agreement with Pappelis et al.<sup>13</sup>

Our results, and those reported by the studies discussed so far, are seemingly in contrast with many large-scale investigations associating CCB exposure to an increased risk of having a glaucoma diagnosis<sup>7–11</sup> or glaucoma-related traits.<sup>10,12</sup> In these studies, the association between CCBs and glaucoma has been largely explored by assessing the likelihood of being diagnosed with POAG in comparison with a control group. Primary open-angle glaucoma was defined using various criteria, ranging from a retrospective extraction of information from EMRs and insurance data,<sup>8,10,11</sup> patient’s self-reporting,<sup>10,11</sup> expert assessment,<sup>7,9</sup> or a combination of these.<sup>9–11</sup> Regardless, all studies, including 1 meta-analysis,<sup>9</sup> showed a significant and generally large increase in the risk of being diagnosed with glaucoma after multivariable adjustment, ranging from 1.239- to 1.87-fold increase. This is also supported by the significant associations reported between CCB use and thinner inner retinal layers measured via OCT imaging<sup>10,12</sup> after multivariable adjustments.

Reconciling these apparently contrasting findings is complicated and might not be possible with the current evidence. These studies are investigating different aspects of the problem, namely the risk of developing glaucoma as opposed to VF progression in patients who have POAG or, as in this study, are being monitored in glaucoma clinics. One explanation for the contrasting results is bias by indication. For example, in the United Kingdom, CCBs are prescribed as second-line treatment for uncontrolled hypertension or as a first-line treatment in patients with Black-African or Black Afro-Caribbean origin or older than 55 years.<sup>39</sup> These patients have a higher risk of developing glaucoma.<sup>4</sup> Although MVAs adjust for age and ethnicity, controlling for complex indications is challenging, potentially linking CCBs to glaucoma despite a possible neuroprotective effect. This hypothesis would add significance to the small difference in rate found in our cohort because it would suggest that CCBs have significantly reduced the rate of VF progression in a potentially fast progressing group of patients. Another alternative hypothesis is that CCBs might induce a type of damage to the optic nerve head that manifests features similar to glaucoma, leading to a diagnosis, but is in fact much less aggressive, resulting in a slower rate of progression when observed longitudinally in clinics. This would explain both the increased risk of a diagnosis of POAG and the apparent neuroprotective effect observed during the follow-up. Of course, this would only explain cases in which the treatment with CCBs was started before the initiation of the follow-up in a glaucoma clinic. However, precise information on the duration of the exposure is often lacking in most of these studies, including ours, and can only be truly assessed accurately in the context of RCTs.<sup>14,15</sup>

The association between CCBs and a higher risk of glaucoma is generally in contrast with their supposed neuroprotective effects. These are usually linked to inhibition of cell apoptosis via a reduction of calcium influx.<sup>40</sup> Moreover, studies in patients have shown a positive effect of CCBs on the blood flow and circulation in the optic nerve head,<sup>41–43</sup> with some reported improvements in visual function.<sup>43</sup> This

might contribute to the reported protective effect in NTG.<sup>14,15</sup> Another supposed mechanism of action of CCBs is to protect and restore the functionality of mitochondria in neurons,<sup>40</sup> which has also been shown, in vitro for amlodipine<sup>44</sup> and in animal models of ocular hypertension for nilvadipine.<sup>45</sup>

Although these mechanisms can explain the association with a slower rate of VF progression, they do not justify the higher risk of developing glaucoma associated with the use of CCBs. The main proposed explanation for this detrimental association is a complex effect on systemic blood pressure of some CCBs, especially when used in combination with other antihypertensive medications.<sup>10</sup> However, this explanation is not supported by our results: most of the patients in our cohort were on CCBs known for their hypotensive properties, such as amlodipine (54%), and a large proportion of CCB users were on other antihypertensive medications, beta-blockers, or diuretics (see Table 1). Despite this, CCBs were associated with a slower rate of VF progression. Interestingly, the estimated association in the MVA remained essentially unchanged when patients on nondihydropyridines were excluded from the analysis (0.031 [0.002–0.060],  $P = 0.034$ , see Supplementary Appendix). Whatever the mechanism, it is likely to be IOP-independent. Despite some evidence of IOP reduction with CCBs use,<sup>46,47</sup> other studies have failed to replicate this effect.<sup>48</sup> Notably, such a lack of association between IOP and CCBs was also reported in a large-scale investigation on the cohort from the UK Biobank.<sup>10</sup> There was no difference in IOP in our cohort (see Table 1).

Despite its strengths, mainly the very large sample size and the long follow-up (Table 1), this study has limitations, largely derived from its retrospective nature. Our sensitivity and secondary analyses were designed to mitigate these limitations. One limitation was the lack of clear diagnostic labels. More than half of the eyes included in the main analysis had not been explicitly labeled as “glaucoma” in the EMR. This is despite having selected patients followed for at least 4 years with at least 2 tests with an MD less than  $-2$  dB. This criterion has been previously used on this dataset to minimize the inclusion of glaucoma suspects and ocular hypertensives,<sup>22–24</sup> but it is clearly not a replacement for a definitive diagnosis. However, many similar investigations relying on the retrospective analysis of medical records or self-reported diagnosis suffer from the same limitation. On the other hand, the selection criteria might have excluded eyes with very early glaucoma or patients with fewer tests prior to surgery, such as fast progressors. Our primary analysis required 5 VFs over at least 4 years; 13% of this cohort was using CCBs. This was no different from the proportion of CCB users (12%) in a larger cohort of patients with at least 2 VFs over 1 year (but fewer than 5 VFs over 4 years), indicating that CCB use was not associated with a shorter follow-up. We included this larger cohort in a sensitivity analysis and obtained similar results (Supplementary Appendix). Our main analysis also truncated VF series at the time of glaucoma surgery, to minimize the systematic bias in the slopes of fast progressing eyes prior to surgery. Cataract surgery might

also affect VF metrics such as MD. However, cataract surgery is usually not offered with the specific goal of treating glaucoma and is, therefore, unlikely to be more commonly performed in fast progressing patients. Regardless, cataract surgery and phakic status were actively controlled for in our PS matching and MVAs. The effect was not significant in our main MVA ( $P = 0.8$ ).

Another limitation was the lack of detailed information on the duration of CCB exposure and the dosage of all systemic medications. Although the duration of exposure could be estimated from the date of first reporting, this estimate is necessarily imprecise (see Methods). However, a sensitivity analysis defining use of CCBs as exposure over at least 20% of the follow-up time confirmed our results, showing a larger difference in the rate of progression (0.07 dB/year or 20% reduction, Supplementary Appendix). We further explored this “dose-response” by performing an additional sensitivity analysis, replacing the binary CCB exposure with a continuous estimate of their exposure fraction (0–1). We found a significant positive association with the exposure fraction (0.13 [0.07–0.19] dB/year per fraction point,  $P < 0.001$ , Supplementary Appendix), confirming our previous results. Note that this analysis would implicate a 0.13 dB/year slower rate of progression, on average, for patients on CCBs for 100% of their follow-up time. However, given the inherent uncertainty around our estimates of exposure duration, we caution against a strict interpretation of these results as a “dose-response.” However, this could suggest that low-level exposure to CCB might have contributed to the small detected difference between CCB users and controls. Another important consideration is that the manual entry of medications by medical staff might be inaccurate, because omissions are impossible to detect. This cohort of patients also lacked ethnic diversity because  $> 90\%$  identified as White, and this limits the generalizability of the findings. Finally, one clear limitation is the lack of an accurate record of the general health of the participants, especially of their cardiovascular status. Some information, especially on the cardiovascular status, can be obtained indirectly from the use of other systemic medications (see the DAG in Supplementary Appendix). Large-scale studies of this kind would benefit from information from primary care providers, to allow for a more careful characterization of the patient’s cohort.

In conclusion, we report evidence of an association between the use of systemic CCBs and slower rate of VF progression in a very large cohort of patients from glaucoma clinics. While this is in agreement with most previous literature on VF progression, it is in apparent contrast with reported evidence of CCBs being linked to a higher risk of developing glaucoma. A comprehensive explanation for this discrepancy remains elusive. It is important to highlight, however, that while statistically significant, the small average estimated difference in rate of VF deterioration between CCB users and controls is unlikely to be clinically meaningful. This should be interpreted in the context of the limitations of this investigation, mainly the lack of precise data on general health and on the duration and dose of CCB exposure. Further analyses with better characterized cohorts

might show different results in specific subgroups. Ultimately, the magnitude of any potential effect, whether

detrimental or protective, could only be estimated with carefully designed RCTs.

## Footnotes and Disclosures

Originally received: February 12, 2025.

Final revision: March 3, 2025.

Accepted: March 7, 2025.

Available online: March 13, 2025. Manuscript no. OGLA-D-25-00054.

<sup>1</sup> NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.

<sup>2</sup> Department of Optometry and Visual Sciences, City St. George's, University of London, London, United Kingdom.

<sup>3</sup> Ophthalmology Unit, University Hospital Maggiore della Carità, Novara, Italy.

<sup>4</sup> Department of Health Sciences, Università del Piemonte Orientale "A. Avogadro", Novara, Italy.

This research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 annual meeting (paper presentation).

Disclosure(s):

All authors have completed and submitted the ICMJE disclosures form.

The authors have made the following disclosures:

G.M.: Grants — Santen, Glaucoma UK; Personal fees — CenterVue, Omikron, Alcon, Enavate Science, Perfuse Therapeutics, Théa, Astellas; Nonfinancial support — Santen; Others — Omikron, Relayer, Théa.

A.R.: Honoraria — Sifi spa; Travel expenses — Thea Farma spa, Bausch + Lomb, Visufarma spa.

D.F.G.-H.: Grants — National Institute for Health Research Evaluation, Trials and Studies Coordinating Centre, Health Technology Assessment (NIHR HTA) Programme 12/35/38.

D.J.F.: Grants — NIHR EME programme (NIHR132758), Alcon Research Institute, Janssen, Santen; Personal fees — Novartis, AbbVie, Santen, Topcon, CenterVue-Revenio, Dompé, Glaucoma Research Foundation, Janssen, Omikron, Santen, Viatrix

G.G.: Grants — Thea, Santen; Consultant — Alcon, Allergan, Balance, Belkin, Ciliattech, Elios, Equinox, Essential Pharma, Genentech/Roche, Glaukos, Iantrek, iStar, Ivantis, McKinsey, Rayner, Reichert, Ripple Therapeutics, Santen, Sight Sciences, Thea, Vialase, Visufarma, Zeiss; Honoraria — Alcon, Allergan, Belkin, Glaukos, Ivantis, Lumibird, McKinsey, Nova EyeMedical, Reichert, Sight Sciences, Thea; Travel expenses — Ivantis, Elios, Thea, NovaEye Medical; Leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid — Clinical Advisory to Patient Advocacy Group GlaucomaUK, Past President of UK & Ireland Glaucoma Society.

G.O.: Grants — Glaucoma UK; Personal fees — Alcon, Precision Vision; Others — Relayer.

D.P.C.: Grants — AbbVie/Allergan, Apellis, Santen; Personal fees — AbbVie/Allergan, Apellis, Théa, Santen, Glaukos, Janssen; Nonfinancial support — Santen.

A.P.K.: Grants — Alcon; Personal fees — AbbVie, Aerie, Google Health, Novartis, Reichert, Santen, Théa, Topcon.

This work and G.M. are supported by funding from Glaucoma UK (2023 Royal College of Ophthalmologists/Glaucoma UK research grant). A.P.K. is supported by a UK Research and Innovation Future Leaders Fellowship, an Alcon Research Institute Young Investigator Award, and a Lister Institute for Preventive Medicine Award. This research was supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology.

The Article Publishing Charge (APC) for this article was paid by Glaucoma UK.

Giovanni Montesano, MD, PhD, an editor of this journal, was recused from the peer-review process of this article and had no access to information regarding its peer-review.

**HUMAN SUBJECTS:** Human subjects' data were used in this study. Subsequent analyses of this dataset were approved by a research ethics committee of City, University of London, in accordance with the Declaration of Helsinki and the General Data Protection Regulation of the European Union. The requirement for informed consent was waived because of the retrospective nature of the study.

No animal subjects were used in this study.

Author Contributions:

Conception and design: Montesano, Rabiolo, Garway-Heath, Khawaja

Data collection: Montesano, Crabb

Analysis and interpretation: Montesano, Rabiolo, Ometto, Khawaja

Obtained Funding: Montesano

Overall responsibility: Montesano, Rabiolo, Garway-Heath, Fu, Gazzard, Ometto, Crabb, Khawaja

Abbreviations and Acronyms:

**ACEi** = angiotensin converting enzyme inhibitor; **ARB** = angiotensin receptor blockers; **BCVA** = best-corrected visual acuity; **CCB** = calcium channel blocker; **DAG** = directed acyclic graph; **EMR** = electronic medical record; **IMD** = index of multiple deprivation; **IOP** = intraocular pressure; **MD** = mean deviation; **MVA** = multivariable analysis; **NTG** = normal tension glaucoma; **POAG** = primary open-angle glaucoma; **PSM** = propensity score matching; **RCT** = randomized clinical trial; **SD** = standard deviation; **VF** = visual field.

Keywords:

Calcium channel blockers, Glaucoma, Progression, Real-world data, Visual fields.

Correspondence:

Anthony P. Khawaja, PhD, FRCOphth, UCL Institute of Ophthalmology, 11-43 Bath St, LMD, EC1V 9EL, United Kingdom. E-mail: [anthony.khawaja@ucl.ac.uk](mailto:anthony.khawaja@ucl.ac.uk).

## References

- Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. *JAMA*. 2005;294:466–472.
- Audi S, Burrage DR, Lonsdale DO, et al. The 'top 100' drugs and classes in England: an updated 'starter formulary' for trainee prescribers. *Br J Clin Pharmacol*. 2018;84:2562–2571.
- Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol*. 2020;16:223–237.
- Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*. 2014;121:2081–2090.

5. Langman MJ, Lancashire RJ, Cheng KK, Stewart PM. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. *Br J Ophthalmol*. 2005;89:960–963.
6. Tham YC, Cheng CY. Associations between chronic systemic diseases and primary open angle glaucoma: an epidemiological perspective. *Clin Exp Ophthalmol*. 2017;45:24–32.
7. Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. *Ophthalmology*. 2007;114:2221–2226.
8. Zheng W, Dryja TP, Wei Z, et al. Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma. *Ophthalmology*. 2018;125:984–993.
9. Vergroesen JE, Schuster AK, Stuart KV, et al. Association of systemic medication use with glaucoma and intraocular pressure: the European eye epidemiology consortium. *Ophthalmology*. 2023;130:893–906.
10. Kastner A, Stuart KV, Montesano G, et al. Calcium Channel blocker use and associated glaucoma and related traits among UK biobank participants. *JAMA Ophthalmol*. 2023;141:956–964.
11. Tavakoli K, Sidhu S, Saseendrakumar BR, et al. Long term systemic use of Calcium Channel blockers and incidence of primary open angle glaucoma. *Ophthalmol Glaucoma*. 2024;7:491–498.
12. Chong RS, Chee ML, Tham YC, et al. Association of anti-hypertensive medication with retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness. *Ophthalmology*. 2021;128:393–400.
13. Pappelis K, Loiselle AR, Visser S, Jansonius NM. Association of systemic medication exposure with glaucoma progression and glaucoma suspect conversion in the groningen longitudinal glaucoma study. *Invest Ophthalmol Vis Sci*. 2019;60:4548–4555.
14. Koseki N, Araie M, Yamagami J, et al. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. *J Glaucoma*. 1999;8:117–123.
15. Koseki N, Araie M, Tomidokoro A, et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. *Ophthalmology*. 2008;115:2049–2057.
16. Daugeliene L, Yamamoto T, Kitazawa Y. Risk factors for visual field damage progression in normal-tension glaucoma eyes. *Graefes Arch Clin Exp Ophthalmol*. 1999;237:105–108.
17. Ishida K, Yamamoto T, Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. *J Glaucoma*. 1998;7:372–377.
18. Kelly SR, Khawaja AP, Bryan SR, et al. Progression from ocular hypertension to visual field loss in the English hospital eye service. *Br J Ophthalmol*. 2020;104:1406–1411.
19. Bengtsson B, Olsson J, Heijl A, Rootzen H. A new generation of algorithms for computerized threshold perimetry, SITA. *Acta Ophthalmol Scand*. 1997;75:368–375.
20. Yohannan J, Wang J, Brown J, et al. Evidence-based criteria for assessment of visual field reliability. *Ophthalmology*. 2017;124:1612–1620.
21. Saunders LJ, Russell RA, Crabb DP. Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm: analysis of large-scale data from clinics. *JAMA Ophthalmol*. 2015;133:74–80.
22. Saunders LJ, Russell RA, Crabb DP. Practical landmarks for visual field disability in glaucoma. *Br J Ophthalmol*. 2012;96:1185–1189.
23. Crabb DP, Saunders LJ, Edwards LA. Cases of advanced visual field loss at referral to glaucoma clinics - more men than women? *Ophthalmic Physiol Opt*. 2017;37:82–87.
24. Boodhna T, Crabb DP. Disease severity in newly diagnosed glaucoma patients with visual field loss: trends from more than a decade of data. *Ophthalmic Physiol Opt*. 2015;35:225–230.
25. Saunders LJ, Russell RA, Kirwan JF, et al. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. *Invest Ophthalmol Vis Sci*. 2014;55:102–109.
26. Rathore M, Shweikh Y, Kelly SR, Crabb DP. Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data. *Eye*. 2023;37:3615–3620.
27. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370:1453–1457.
28. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw*. 2015;67:1–48.
29. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. *J Stat Softw*. 2017;82:1–26.
30. Textor J, van der Zander B, Gilthorpe MS, et al. Robust causal inference using directed acyclic graphs: the R package “dagitty”. *Int J Epidemiol*. 2016;45:1887–1894.
31. Ho D, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. *J Stat Softw*. 2011;42:1–28.
32. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained Equations in R. *J Stat Softw*. 2011;45:1–67.
33. Montesano G, Crabb DP, Wright DM, et al. Estimating the distribution of true rates of visual field progression in glaucoma. *Transl Vis Sci Technol*. 2024;13:15.
34. Akaike H. A new look at the statistical model identification. *IEEE Trans Automatic Control*. 1974;19:716–723.
35. Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. *Am J Epidemiol*. 2013;177:292–298.
36. Wright DM, Konstantakopoulou E, Montesano G, et al. Visual field outcomes from the multicenter, randomized controlled laser in glaucoma and ocular hypertension trial (LiGHT). *Ophthalmology*. 2020;127:1313–1321.
37. Montesano G, Ometto G, Ahmed IIK, et al. Five-year visual field outcomes of the HORIZON trial. *Am J Ophthalmol*. 2023;251:143–155.
38. Faraway JJ. *Extending the linear model with R (texts in statistical science)*. Boca Raton, FL: Chapman & Hall/CRC Taylor & Francis Group; 2005.
39. NICE. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Natl Inst Health Care Excell. <https://www.nice.org.uk/guidance/ng136>; 2019. Accessed July 8, 2024.
40. Araie M, Mayama C. Use of calcium channel blockers for glaucoma. *Prog Retin Eye Res*. 2011;30:54–71.
41. Yamamoto T, Niwa Y, Kawakami H, Kitazawa Y. The effect of nilvadipine, a calcium-Channel Blocker, on the hemodynamics of retrobulbar vessels in normal-tension glaucoma. *J Glaucoma*. 1998;7:301–305.
42. Tomita G, Niwa Y, Shinohara H, et al. Changes in optic nerve head blood flow and retrobulbar hemodynamics following calcium-channel blocker treatment of normal-tension glaucoma. *Int Ophthalmol*. 1999;23:3–10.

43. Luksch A, Rainer G, Koyuncu D, et al. Effect of nimodipine on ocular blood flow and colour contrast sensitivity in patients with normal tension glaucoma. *Br J Ophthalmol*. 2005;89:21.
44. Park H-H, Han M-H, Choi H, et al. Mitochondria damaged by oxygen glucose deprivation can be restored through activation of the PI3K/akt pathway and inhibition of calcium influx by amlodipine camsylate. *Sci Rep*. 2019;9:15717.
45. Tsuruga H, Murata H, Araie M, Aihara M. Neuroprotective effect of the calcium channel blocker nilvadipine on retinal ganglion cell death in a mouse ocular hypertension model. *Heliyon*. 2023;9:e13812.
46. Schnell D. Response of intraocular pressure in normal subjects and glaucoma patients to single and repeated doses of the coronary drug adalat. In: Lochner W, Braasch W, Kroneberg G, eds. *2nd International Adalat Symposium: New Therapy of Ischemic Heart Disease*. Berlin, Heidelberg: Springer Berlin Heidelberg; 1975.
47. Monica ML, Hesse RJ, Messerli FH. The effect of a calcium-channel blocking agent on intraocular pressure. *Am J Ophthalmol*. 1983;96:814.
48. Kelly SP, Walley TJ. Effect of the calcium antagonist nifedipine on intraocular pressure in normal subjects. *Br J Ophthalmol*. 1988;72:216.